77 related articles for article (PubMed ID: 23375287)
1. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation.
Chakkera HA; Chang YH; Bodner JK; Behmen S; Heilman RL; Reddy KS; Mulligan DC; Moss AA; Khamash H; Katariya N; Hewitt WR; Pitta TL; Frassetto LA
Transplant Proc; 2013; 45(1):137-41. PubMed ID: 23375287
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
4. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis.
Liu YY; Li C; Cui Z; Fu X; Zhang S; Fan LL; Ma J; Li G
Gene; 2013 Dec; 531(2):476-88. PubMed ID: 24042126
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
6. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
Akbas SH; Bilgen T; Keser I; Tuncer M; Yucetin L; Tosun O; Gultekin M; Luleci G
Transplant Proc; 2006 Jun; 38(5):1290-2. PubMed ID: 16797284
[TBL] [Abstract][Full Text] [Related]
7. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients.
Grover A; Frassetto LA; Benet LZ; Chakkera HA
Drug Metab Dispos; 2011 Nov; 39(11):2017-9. PubMed ID: 21849516
[TBL] [Abstract][Full Text] [Related]
11. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
12. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms and individualized tacrolimus dosing.
López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
Li D; Gui R; Li J; Huang Z; Nie X
Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients.
Li Y; Hu X; Cai B; Chen J; Bai Y; Tang J; Liao Y; Wang L
Transpl Immunol; 2012 Aug; 27(1):12-8. PubMed ID: 22504573
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
19. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
[TBL] [Abstract][Full Text] [Related]
20. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]